Working… Menu

Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04155749
Recruitment Status : Recruiting
First Posted : November 7, 2019
Last Update Posted : May 20, 2021
Information provided by (Responsible Party):
Arcellx, Inc.

Brief Summary:
Master protocol for cell therapy, Phase 1 proof-of-concept studies., in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

Condition or disease Intervention/treatment Phase
Relapsed and Refractory Multiple Myeloma Drug: CART-ddBCMA Phase 1

Detailed Description:
ARM 1 is a, non-randomized, open label, multi-site Phase 1 study. CART-ddBCMA is a BCMA directed CAR with a non-scFv binding domain that has been deimmunized.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, Including Long-term Safety Follow-up
Actual Study Start Date : November 18, 2019
Estimated Primary Completion Date : November 1, 2021
Estimated Study Completion Date : November 1, 2035

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: ARM 1
Phase I study of BCMA-specific CAR-modified T-cell therapy using alternative binding domain, for the treatment of patients with relapsed and refractory multiple myeloma
Chimeric Antigen Receptor T cells

Primary Outcome Measures :
  1. Incidence of treatment-emergent adverse events (TEAEs), including DLT(s) [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Best overall response (BOR) and ORR by IMWG Consensus Criteria [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Relapsed and refractory Multiple Myeloma treated with at least 3 prior regimens of system therapy including Proteosome Inhibitor (PI), immunomodulatory drugs (IMiD), and anti-CD38 antibody (CD38mab); or has "triple-refractory" disease
  • Documented measurable disease
  • Adequate organ function
  • Life expectancy > 12 weeks, Eastern Cooperative Group Performance Status 0-1

Exclusion Criteria:

  • Plasma Cell Leukemia or History of Plasma Cell Leukemia
  • Patients with a history of severe hypersensitivity to DMSO should be excluded
  • Contraindication to fludarabine or cyclophosphamide
  • Severe uncontrolled intercurrent illness (e.g., infection) or laboratory abnormalities
  • Active central nervous system disease involvement by malignancy or active CNS pathology

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04155749

Layout table for location contacts
Contact: Arcellx, Inc. 240-327-0379

Layout table for location information
United States, Illinois
University of Chicago Medicine Comprehensive Cancer Center Recruiting
Chicago, Illinois, United States, 60637
Contact: Melissa Sheppard, BSN, RN    773-702-2476   
Contact: Rebecca Malloy, RN, BSN    773-834-1475   
Principal Investigator: Michael Bishop, MD         
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Matthew Frigault, MD    617-724-4000   
Principal Investigator: Matthew Frigault, MD         
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Emma Logan, BSN, RN, OCN    617-667-5984   
Principal Investigator: Jacalyn Rosenblatt, MD         
Sponsors and Collaborators
Arcellx, Inc.
Layout table for investigator information
Study Director: Arcellx, Inc. Arcellx, Inc.
Layout table for additonal information
Responsible Party: Arcellx, Inc. Identifier: NCT04155749    
Other Study ID Numbers: ARC-101
First Posted: November 7, 2019    Key Record Dates
Last Update Posted: May 20, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Arcellx, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases